{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012630","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.398989+00:00","generated_at":"2026-05-17T08:21:51.362880+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M","bullets":["Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.","7 patients dosed in combination with tislelizumab; first 3 evaluable: 1 stable disease, 2 progression.","Raised $5.7M gross proceeds from convertible notes converted to common stock and pre-funded warrants in July 2025.","Monotherapy portion completed; initial combination safety cohort dosing ongoing, with initial data expected later in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012630","json":"https://secwatch.observer/filing/0001493152-25-012630.json","markdown":"https://secwatch.observer/filing/0001493152-25-012630.md","text":"https://secwatch.observer/filing/0001493152-25-012630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225012630/0001493152-25-012630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225012630/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:21:51.362880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}